Coronary Arteriosclerosis: Clinical Trials

22 trials for Coronary Arteriosclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 3 unknown, 2 terminated. 22 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 422Completed 17, Unknown 3, Terminated 2

Follow Coronary Arteriosclerosis: new trials by email Literature Review of Coronary Arteriosclerosis trials Research Report on Coronary Arteriosclerosis

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Effects of Allicor on Patients After Coronary Arteria Revascularization Treatment
Allicor, Placebo - Myocardial Ischemia, Coronary Artery Bypass Grafting
Phase 4UnknownInstitute for Atherosclerosis Research, Russia2002023-04-102023-04-19
EARly Prevention of aTHeroma Progression
Standard Therapy, Rosuvastatin - Coronary Arteriosclerosis
Phase 4TerminatedCHEOL WHAN LEE, M.D., Ph.D1112014-06-012018-06-25
Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease
Ivabradine, Placebo - Coronary Artery Disease, Coronary Arteriosclerosis
Phase 4UnknownUniversity Hospital, Saarland502012-12-012013-01-15
The Elderly ACS II Trial
prasugrel, Clopidogrel - Acute Coronary Syndrome, Coronary Arteriosclerosis
Phase 4CompletedAzienda USL Reggio Emilia - IRCCS14572012-11-012025-06-24
Aspirin Reload Before Percutaneous Coronary Intervention: Reperfusion Indexes Evaluation.
Aspirin - Coronary Arteriosclerosis
Phase 4CompletedUniversity of Roma La Sapienza1002011-01-012013-05-14
XIENCE V: SPIRIT WOMEN Sub-study
XIENCE V®/ XIENCE PRIME™, CYPHER SELECT - Coronary Artery Stenosis, Coronary Arteriosclerosis
Phase 4CompletedAbbott Medical Devices4552008-09-012012-08-07
XIENCE V: SPIRIT WOMEN
XIENCE V®/ XIENCE PRIME™ - Coronary Artery Stenosis, Coronary Arteriosclerosis
Phase 4CompletedAbbott Medical Devices16002007-07-012015-05-13
Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease
Paracetamol - Coronary Arteriosclerosis, Endothelial Function
Phase 4CompletedUniversity of Zurich372006-11-012019-12-03
YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus
Yukon Choice stent system, Taxus Liberté stent system - Coronary Arteriosclerosis
Phase 4CompletedUniversity of Leipzig2402006-09-012010-02-02
Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
Multidetector Computed Tomography Coronary Angiography - Coronary Arteriosclerosis, Cardiomyopathies
Phase 4CompletedSt. Joseph's Healthcare Hamilton1682006-09-012010-11-25
Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)
Iodixanol 320, Iomeprol 350 - Renal Insufficiency, Chronic, Angioplasty, Transluminal, Percutaneous Coronary
Phase 4CompletedDeutsches Herzzentrum Muenchen3242006-07-012010-03-15
Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment
Integration of a team based clinical pharmacist, Optimizing therapeutic treatments, Optimizing processes of care - Heart Failure, Congestive, Pulmonary Disease, Chronic Obstructive
Phase 4CompletedUniversity of Alberta4522006-02-012007-12-11
The Low HDL On Six Weeks Statin Therapy (LOW) Study
Nicotinic acid - HDL Cholesterol, Coronary Arteriosclerosis
Phase 4UnknownCraigavon Area Hospital602005-11-012006-09-13
Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)
Ezetimibe, Placebo, Atorvastatin 10 mg - Hypercholesterolemia, Coronary Arteriosclerosis
Phase 4CompletedOrganon and Co222005-09-012022-02-09
Effects of Celecoxib After Percutaneous Coronary Intervention
Celecoxib - Coronary Arteriosclerosis
Phase 4CompletedSeoul National University Hospital2602004-08-012011-07-21
Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients
modified-release dipyridamole/aspirin, aspirin - Coronary Arteriosclerosis
Phase 4CompletedBoehringer Ingelheim112004-04-012025-01-23
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
Atorvastatin (Lipitor) - Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Phase 4CompletedPfizer's Upjohn has merged with Mylan to form Viatris Inc.20802003-01-012021-02-18
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
Atorvastatin (Lipitor) - Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Phase 4CompletedPfizer's Upjohn has merged with Mylan to form Viatris Inc.5952003-01-012021-02-18
Comparative Atorvastatin Pleiotropic Effects
Blood samples, Atorvastatin - Coronary Arteriosclerosis, Hypercholesterolemia
Phase 4CompletedPfizer's Upjohn has merged with Mylan to form Viatris Inc.3302002-06-012021-02-18
Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism
telmisartan 40 mg, placebo 40 mg - Hypertension, Coronary Arteriosclerosis
Phase 4CompletedBoehringer Ingelheim422001-12-012013-11-01

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Coronary Artery Disease (22)  ·  Myocardial Ischemia (4)  ·  Diabetes Mellitus, Type 2 (3)  ·  Coronary Restenosis (2)  ·  Coronary Stenosis (2)  ·  Dyslipidemias (2)  ·  Hypercholesterolemia (2)  ·  Hypertension (2)  ·  Peripheral Vascular Diseases (2)  ·  Stroke (2)  ·  Vascular Diseases (2)  ·  Acute Coronary Syndrome (1)  ·  Cardiomyopathies (1)  ·  Cardiovascular Diseases (1)  ·  Heart Defects, Congenital (1)

Broader conditions

Arterial Occlusive Diseases (22)  ·  Arteriosclerosis (22)  ·  Coronary Disease (22)  ·  Heart Diseases (22)  ·  Cardiovascular Diseases (21)  ·  Vascular Diseases (20)  ·  Myocardial Ischemia (18)  ·  Metabolic Diseases (5)  ·  Nutritional and Metabolic Diseases (5)  ·  Lipid Metabolism Disorders (4)  ·  Diabetes Mellitus (3)  ·  Endocrine System Diseases (3)  ·  Glucose Metabolism Disorders (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)

Interventions

Atorvastatin (5)  ·  Aspirin (2)  ·  Telmisartan (2)  ·  Acetaminophen (1)  ·  Blood Specimen Collection (1)  ·  Celecoxib (1)  ·  Clopidogrel (1)  ·  Ezetimibe (1)  ·  Ivabradine (1)  ·  Niacin (1)  ·  Prasugrel Hydrochloride (1)  ·  Pravastatin (1)  ·  Rosuvastatin Calcium (1)  ·  Standard of Care (1)  ·  iodixanol (1)

Sponsors

Boehringer Ingelheim (3)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (3)  ·  Abbott Medical Devices (2)  ·  Azienda USL Reggio Emilia - IRCCS (1)  ·  CHEOL WHAN LEE, M.D., Ph.D (1)  ·  Craigavon Area Hospital (1)  ·  Deutsches Herzzentrum Muenchen (1)  ·  Institute for Atherosclerosis Research, Russia (1)  ·  Organon and Co (1)  ·  Pfizer (1)  ·  Seoul National University Hospital (1)  ·  St. Joseph's Healthcare Hamilton (1)  ·  University Hospital, Saarland (1)  ·  University of Alberta (1)  ·  University of Leipzig (1)

Countries

Germany (7)  ·  Italy (5)  ·  Canada (4)  ·  Poland (4)  ·  Russia (4)  ·  Switzerland (4)  ·  France (3)  ·  Hungary (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Argentina (2)  ·  Austria (2)  ·  Belgium (2)  ·  Brazil (2)  ·  Denmark (2)

Top investigators

Marie-Claude Morice (2)  ·  Stephan Windecker (2)  ·  Alan Moody, MD (1)  ·  Albert Schoemig, MD (1)  ·  Benjamin Chow, MD (1)  ·  Bon-Kwon Koo, MD, PhD (1)  ·  Frank Ruschitzka, MD (1)  ·  Gaetano Tanzilli, Prof. (1)  ·  Holger Thiele, MD (1)  ·  I Menown, MD FRCP (1)  ·  Marcello Dominici, MD (1)  ·  Michael Freeman, MD (1)

Results publications

PMID 17626713, PMID 17707751, PMID 19167589, PMID 19217176, PMID 19234987, PMID 19433997, PMID 20031753, PMID 20484099, PMID 20956208, PMID 21403014, PMID 21511226, PMID 21610204, PMID 23873579, PMID 25074252, PMID 25940520, PMID 27823681, PMID 28796809, PMID 29459361, PMID 30636561

NIH funding

2004 (1)